Abstract:Aims: To evaluate the effects of chimerism on the mice heart transplanted survival with the bone marrow infusion. Methods: Bone marrow cells (BMCs) were obtained from BALB/c mice. These BMCs were injected into the irradiated (2Gy-Co60) C57BL/6 mice through femoral vein. Then Group A mice were treated with Cyclosporine (1 mg/kg) for 21 days and Group B were not treated with Cyclosporine. Group C were treated as the control group without BMCs infusion. Group D were treated with Cyclosporine (1 mg/kg) for 21 days pre-hearttransplantation without BMCs infusion. After 21 days, the C57BL/6 mice received heart allografts from BALB/c. To determine the degree of chimerism in BMCs infusion recipients, peripheral blood were isolated on day 7, 14, 21. Allografts were harvested 10 days after heart transplantation for the histological analysis. Results: (1) Chimerism detected in the peripheral blood of Group A mice on day 7 after BMCs infusion was 6.1 +/- 2.5%, on day 14 was 15.4 +/- 2.9% and on day 21 was 10.7 +/- 2.6%. For the Group B mice on day 7 after BMCs infusion, the chimerism was 2.8 +/- 1.1%, on day 14 was 11.2 +/- 4.8% and on day 21 was 7.4 +/- 3.7%. For the Groups C and D mice, no chimerism was observed. Group A mice had the tendency toward improved level of chimerism than Group B mice. (2) The survival time of Group A (n = 6) was 13.0 +/- 1.4 days which was significantly longer than Group B (n = 6) with the survival time was 8.5 +/- 1.3 days (p<0.001), also longer than the mice in Groups C and D, the survival time of which were 10.0 +/- 1.3 days (p = 0.008) and 9.4 +/- 1.1 days (p = 0.004). There is no significant difference among Groups B, C, and D. (3) The HE staining showed the much more seriously heart rejection in Groups B, C and D than Group A. Conclusions: The chimerism was found in the BMCs infusion groups. Without the CsA treatment combined with chimerism could not protect the transplanted heart. There was no obvious evidence showed that the chimerism alone could improve the survival time of cardiac allografts in mice. Published by Elsevier B.V.

Prognosis of Endothelial Chimerism in Renal Allograft

Endothelial chimerism in renal allograft

Endothelial Cell Chimerism by Fluorescence in Situ Hybridization in Gender Mismatched Renal Allograft Biopsies

Application of fluorescence in situ hybridization in analyzing endothelial chimerism in renal allograft

Prediction of Subclinical Renal Allograft Rejection by Vascular Endothelial Growth Factor in Serum and Urine.

Biomarkers for Renal Transplantation: Where Are We?

Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology

Histological Isolated Endarteritis Benefits Glomerular Filtration Rate And Allograft Survival After Anti-Rejection Treatment

Effects of chimerism on the mice heart transplanted survival with the bone marrow infusion.

Effect of early and late endarteritis upon clinical prognosis after renal transplantation

Postreperfusion Renal Allograft Biopsy Predicts Outcome of Single-Kidney Transplantation: A 10-Year Observational Study in China

[Clinical Significance of Dynamic Monitoring of Cell Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation].

[Influence of Pre-Transplant Serum Level of Soluble CD30 on the Long-Term Survival Rates of Kidney Transplant Recipients and Grafts].

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

Outcomes of Allograft from Donor Kidney Microthrombi and Secondary Recipient Thrombotic Microangiopathy: Should We Consider Loosening the Belt?

Feasibility of Diagnosing Renal Allograft Dysfunction by Oligonucleotide Array: Gene Expression Profile Correlates with Histopathology.

High Serum Level of the Soluble CD30 Identifies Chinese Kidney Transplant Recipients at High Risk of Unfavorable Outcome

Pre-transplant Serum Concentrations of Anti-Endothelial Cell Antibody in Panel Reactive Antibody Negative Renal Recipients and Its Impact on Acute Rejection

Long term follow up of renal transplant recipients with borderline change

Quantitative Assessment Of Hematopoietic Chimerism After Allogeneic Nonmyeloalblative Stem Cell Transplantation.

Short Tandem Repeat Analysis in a Living Related Donor Adult Renal Transplant Recipient with Rare Natural Chimerism.